Hims & Hers: The Novo Nordisk Deal Changes Everything (NYSE:HIMS)

The Novo Nordisk partnership legitimizes Hims & Hers’ business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution.

You are being redirected to the original discussion. Please continue if you want to read the full post.

Continue to original article

You will be redirected in 3 seconds.

liveinternet liveinternet